Volume | 16,907 |
|
|||||
News | - | ||||||
Day High | 3.14 | Low High |
|||||
Day Low | 3.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NeuroBo Pharmaceuticals Inc | NRBO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.07 | 3.00 | 3.14 | 3.14 | 3.06 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
206 | 16,907 | $ 3.08 | $ 52,133 | - | 2.8888 - 6.7499 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 6 | $ 3.10 | USD |
NeuroBo Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
14.8M | 4.85M | - | 0 | -12.47M | -2.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NeuroBo Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRBO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.44 | 3.4999 | 2.99 | 3.12 | 25,444 | -0.30 | -8.72% |
1 Month | 4.12 | 4.33 | 2.99 | 3.55 | 25,579 | -0.98 | -23.79% |
3 Months | 5.53 | 6.7499 | 2.99 | 5.23 | 257,064 | -2.39 | -43.22% |
6 Months | 3.44 | 6.7499 | 2.90 | 5.32 | 708,518 | -0.30 | -8.72% |
1 Year | 5.36 | 6.7499 | 2.8888 | 5.01 | 498,882 | -2.22 | -41.42% |
3 Years | 849.60 | 1,576.80 | 2.8888 | 253.14 | 1,069,385 | -846.46 | -99.63% |
5 Years | 2,196.00 | 7,200.00 | 2.8888 | 312.96 | 775,123 | -2,192.86 | -99.86% |
NeuroBo Pharmaceuticals Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. |